E. Ohman J or Asset Management AB Lowers Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

E. Ohman J or Asset Management AB decreased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 16.8% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 70,611 shares of the medical research company's stock after selling 14,252 shares during the quarter. Thermo Fisher Scientific makes up 0.9% of E. Ohman J or Asset Management AB's investment portfolio, making the stock its 28th largest position. E. Ohman J or Asset Management AB's holdings in Thermo Fisher Scientific were worth $35,136,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Semus Wealth Partners LLC boosted its holdings in Thermo Fisher Scientific by 4.0% during the 4th quarter. Semus Wealth Partners LLC now owns 471 shares of the medical research company's stock valued at $245,000 after acquiring an additional 18 shares during the period. Revolve Wealth Partners LLC lifted its holdings in shares of Thermo Fisher Scientific by 4.2% in the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock worth $255,000 after buying an additional 20 shares during the period. Proactive Wealth Strategies LLC lifted its holdings in shares of Thermo Fisher Scientific by 2.7% in the 4th quarter. Proactive Wealth Strategies LLC now owns 753 shares of the medical research company's stock worth $392,000 after buying an additional 20 shares during the period. Cassaday & Co Wealth Management LLC lifted its holdings in shares of Thermo Fisher Scientific by 0.9% in the 4th quarter. Cassaday & Co Wealth Management LLC now owns 2,286 shares of the medical research company's stock worth $1,189,000 after buying an additional 20 shares during the period. Finally, Callan Capital LLC lifted its holdings in shares of Thermo Fisher Scientific by 2.7% in the 4th quarter. Callan Capital LLC now owns 773 shares of the medical research company's stock worth $402,000 after buying an additional 20 shares during the period. Institutional investors own 89.23% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on TMO shares. Wall Street Zen upgraded Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a report on Wednesday, May 21st. Scotiabank lowered their target price on Thermo Fisher Scientific from $650.00 to $605.00 and set a "sector perform" rating for the company in a report on Friday, April 25th. Stifel Nicolaus lowered their target price on Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating for the company in a report on Thursday, April 24th. The Goldman Sachs Group set a $610.00 price target on Thermo Fisher Scientific and gave the stock a "buy" rating in a research report on Wednesday, April 23rd. Finally, UBS Group reduced their price target on Thermo Fisher Scientific from $715.00 to $500.00 and set a "buy" rating for the company in a research report on Thursday, April 24th. Four equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $605.30.

Thermo Fisher Scientific Stock Up 0.9%

NYSE:TMO traded up $3.63 during mid-day trading on Friday, hitting $401.99. 2,629,538 shares of the company's stock traded hands, compared to its average volume of 1,908,231. The company has a fifty day moving average of $420.74 and a 200 day moving average of $495.93. Thermo Fisher Scientific Inc. has a twelve month low of $390.50 and a twelve month high of $627.88. The company has a market capitalization of $151.75 billion, a P/E ratio of 24.32, a P/E/G ratio of 2.99 and a beta of 0.78. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, beating analysts' consensus estimates of $5.10 by $0.05. The business had revenue of $10.36 billion for the quarter, compared to analyst estimates of $10.23 billion. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. The company's revenue was up .2% on a year-over-year basis. During the same period in the prior year, the company earned $5.11 earnings per share. On average, analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 15th. Stockholders of record on Friday, June 13th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.43%. The ex-dividend date is Friday, June 13th. Thermo Fisher Scientific's dividend payout ratio is presently 10.09%.

Insider Activity

In other news, SVP Michael A. Boxer sold 3,775 shares of the company's stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $532.52, for a total value of $2,010,263.00. Following the sale, the senior vice president now owns 10,816 shares in the company, valued at $5,759,736.32. This represents a 25.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Gianluca Pettiti sold 300 shares of the company's stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $429.93, for a total value of $128,979.00. Following the completion of the sale, the executive vice president now owns 23,167 shares in the company, valued at $9,960,188.31. The trade was a 1.28% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.